Keyword: Revolution Medicines
The anticipated fundraising haul will bankroll development of a pipeline of RAS programs up to the completion of IND-enabling studies.
Revolution Medicines raised $100 million in series C financing to advance a stable of drugs aiming at what it calls “frontier targets” in cancer.
Revolution Medicines is acquiring Warp Drive Bio, planning to combine the two companies’ drug discovery efforts and precision cancer therapy programs.
The partners plan to move small molecule SHP2 inhibitor RMC-4630 into the clinic later this year.
The capital will push Revolution's lead program, a SHP2 inhibitor, into the clinic.